Tumour growth is dependent upon a blood supply and is associated with the switch to the angiogenic phenotype. We are developing strategies for targeting gene expression to endothelial cells in the tumour vasculature. Recombinant retroviruses have been generated that incorporate regulatory sequences of the prepro-endothelin-1 (ppET1) promoter. Following reverse transcription and integration these modifications are duplicated in the proviral 5Ј LTR for transcription of the internal ␤-galactosidase reporter gene. The titres and endothelial specificity of retroviral vectors harbouring different modifications have been analysed. In the optimal strategy, replacing the MLV enhancer with ppET1 promoter sequences containing the GATA and AP1 elements whilst
Introduction
Tumour growth is dependent upon a blood supply and is associated with the switch to the angiogenic phenotype. 1, 2 Anti-angiogenic drugs have been shown to slow tumour growth, 3, 4 whilst angiostatin and endostatin, endogenous inhibitors of angiogenesis, can also cause tumour regression. [5] [6] [7] Vascular damage in experimental tumours treated with doxorubicin targeted to the tumour blood vessels, has also resulted in reduced tumour growth and prolonged survival time. 8 We are developing vectors for targeting gene expression to tumour vasculature as a strategy for cancer gene therapy. Ultimately we are aiming to produce vectors suitable for systemic delivery following intravenous injection, that will specifically lead to the destruction of tumour vasculature. The relatively high turnover of endothelial cells within tumour vasculature 9 provides one level of specificity when using murine retroviral vectors due to their dependence on cell division for integration and expression. However, for reasons of safety and efficiency additional levels of specificity will be required, such as restriction of expression to the intended target cells.
The transcriptional activity of the LTR U3 region has been previously modified by addition of, or replacement with, heterologous enhancer and/or promoter sequences. The murine leukemia virus (MLV) enhancer consists of a 75 bp direct repeat, within which binding sites for Correspondence: CD Porter Received 9 August 1999; accepted 13 October 1999 maintaining sequences from the viral promoter resulted in endothelial cell-specific expression of the reporter gene, and viral titres comparable to those of the unmodified vector. A panel of endothelial and non-endothelial cells infected with the modified virus from a high titre producer clone showed a pattern of expression consistent with the activity of the endogenous ppET1 promoter. The modified LTR retained specificity in vivo, in subcutaneous tumours arising from the co-injection of tumour cells and irradiated virus producer cells. This simple model achieves high efficiency of transduction and can be used routinely for the screening of targeted retroviral vectors. Gene Therapy (2000) 7, 368-376.
nuclear factors have been identified, and the proximal promoter contains both the CAAT and TATA boxes. Whilst there is no strong cell specificity associated with the MLV LTR, replacement of U3 with an equivalent region of the LTR from related murine retroviruses modified specificity. 10, 11 Similarly, replacement of the MLV enhancer with that of a polyoma mutant selected to grow in embryonal carcinoma cells overcame the MLV LTR restriction in these cells. 12 Insertion of the muscle creatine kinase enhancer between the viral enhancer and promoter resulted in differentiation-specific expression in myogenic cells. 13 However, appropriate cell specificity was not obtained in this latter case nor following addition of lymphoid-specific enhancers.
14 In contrast, replacement of the viral enhancer elements with the tyrosinase enhancer or replacement of the viral enhancer and promoter elements with the tyrosinase enhancer and promoter led to specific expression in melanoma cells. 15, 16 In a recent report, replacement of the viral enhancer with the GATA-1 autoregulatory enhancer led to specific expression in erythroblastoid cells. 17 We have generated retroviral vectors with modified LTRs incorporating promoter sequences of the human prepro-endothelin-1 (ppET1) gene. Prepro-endothelin-1 is expressed in a wide range of endothelial cells 18, 19 and its promoter has been well characterised in vitro. 20, 21 We have compared different strategies of replacing the MLV enhancer and/or promoter with the promoter region of the human ppET1 gene or a more restricted sequence containing the GATA and AP1-like elements, known to be essential for endothelial specificity. [21] [22] [23] We found that it was necessary to maintain the proximal promoter sequences of the viral LTR in order to obtain optimal titres, whilst replacement of the viral enhancer with proximal ppET1 promoter sequences containing the GATA and AP1 elements resulted in endothelial cellspecific expression of the reporter gene. A high titre virus was generated that exhibits endothelial specificity both in vitro and in vivo.
Results

Cloning of ppET1 promoter sequences
Previous studies have demonstrated that the −141 bp to +145 bp (relative to the transcriptional start site) region of the ppET1 gene can drive expression of a reporter gene specifically in endothelial cells in transient transfection assays. 20, 21 A DNA fragment incorporating this region, as well as a shorter fragment (−177 to +33) containing less downstream sequence (Figure 1 ), showed orientationdependent promoter activity in CPAE (calf pulmonary artery endothelial) cells but not in 3T3 fibroblasts (data not shown). The −177 to +33 fragment was subsequently used to replace the promoter/enhancer region of the MLV 3Ј LTR and so generate retroviral vectors with hybrid LTRs.
Generation of retroviral vectors with hybrid LTR by replacement of the MLV promoter/enhancer region
The −177 to +33 promoter region of the ppET1 gene was used to replace the viral promoter and enhancer sequences in the 3Ј LTR by insertion between the NheI and SstI sites (hybrid A; Figure 2 ) in the vector pNeoMFGnlslacz. In this vector the neo R selection cassette is positioned outside the retroviral sequences, to avoid interference of the strong SV40 promoter with the hybrid LTR. To address potential problems in the initiation of transcription due to the presence of two TATA boxes in hybrid A, a second vector was also generated (hybrid B; Figure 2 ), in which the enhancer/promoter region of the Gene Therapy viral LTR was replaced with a smaller sequence (nucleotides −177 to −37), lacking the ppET1 promoter TATA box. The viral TATA box and following sequences were not replaced in these vectors, since the terminal bases of U3 are necessary for recognition of the polyadenylation signal in the 3Ј LTR. 24 Virus harvested from bulk populations of stable TE-FLY-A8 transfectants was used to infect PAE and TE671 target cells. Endogenous expression in PAE cells was confirmed by RT-PCR using primers specific for porcine ppET1, whereas no endogenous expression was detected in TE671 cells (data not shown) that were subsequently used as a negative control. Reporter gene expression driven by the hybrid LTRs was determined by means of histochemical staining, although this could be affected by both the expression level, as well as the transduction efficiency of the infected cells. In order to overcome differences in the intrinsic infectability of PAE and TE671 cells, titres were expressed as percentage of the control vector pNeoMFGnlslacz. The histochemical titre of hybrid viruses A and B was approximately 14% of that of the unmodified virus in PAE cells, compared with less than 1% in TE671 cells (Figure 2 ). Therefore replacement of the viral promoter and enhancer region with either the −177 to +33 or the −177 to −37 promoter sequences of the ppET1 gene conferred endothelial cell transcriptional specificity, although the modification also resulted in reduced histochemical titre in PAE cells.
To test whether incorporation of the viral enhancer or an heterologous enhancer, aiming to up-regulate the expression level driven by the hybrid LTR in hybrid B, would affect the histochemical titre, hybrids C and D were constructed to incorporate the MLV and CMV enhancers, respectively ( Figure 2 ). There was up-regulation of histochemical titre to 24% of that of the unmodified virus in the presence of the CMV enhancer and 19% in the presence of the MLV enhancer. This suggested that the loss of titre of hybrid B was largely due to reduced transduction efficiency, although there could be a smaller promoter component, a result of either the hybrid modification or the intrinsic activity of the ppET1 promoter.
Generation of retroviral vectors with hybrid LTR by replacement of the MLV enhancer region
The transcriptional activity of the LTR U3 region has been previously modified by replacement of the viral enhancer with heterologous enhancers, without reported loss of titre. 12, [15] [16] [17] We sought to explore the possibility of modulating the viral promoter activity using proximal regulatory sequences of the ppET1 promoter, in retroviral vectors in which only the viral enhancer was replaced. The −177 to +33 and the −177 to −37 promoter sequences of the ppET1 gene were used to replace the viral enhancer between the NheI and XbaI sites, to generate hybrids E and F, respectively ( Figure 2 ). In hybrid E the entire ppET1 promoter including the viral TATA box was incorporated, whereas in hybrid F only regulatory sequences upstream of the ppET1 promoter TATA box were used to replace the viral enhancer. Virus harvests from stable transfectants of TE-FLY-A8 packaging cells were used to infect PAE and TE671 cells. Hybrid E showed some reduced histochemical staining compared with the control virus, whereas hybrid F retained both high titre and specificity for PAE cells ( Figure 2) .
A producer cell clone of hybrid F virus was generated with high titre on PAE cells, ELH-F20 (ETP/LTR hybrid F, clone 20). Southern blot analysis of DNA from infected cells using the nlslacz gene as a probe, revealed a hybridizing species of approximately 5.5 kb that corresponded to the intact ELH-F20 provirus (Figure 3 ). High titre MFGnlslacz virus from the producer clone TELCe-B6AF 25 was used as a control. The histochemical titre of the control virus was of the order of 5 × 10 6 c.f.u./ml in PAE cells. The multiplicity of infection of target PAE cells infected with ELH-F20 at 1:10 dilution and control virus MFGnlslacz at 1:100 dilution was calculated both by histochemical staining, and quantitative Southern blot analysis of vector copy number. The calculated MOI from the histochemical staining for both ELH-F20 and for MFGnlslacz was in good agreement with the vector copy number in infected PAE cells, calculated from the corresponding hybridizing bands and plasmid copy number equivalents ( Table 1 ). The proviral copy number was determined from Southern blot analysis using plasmid copy number equivalents for quantitation (see Figure 3) . its viral titre in PAE cells. Similarly, the MOIs calculated by histochemical staining and Southern blot analysis of target PAE cells infected with hybrid B virus from a high titre producer clone were also comparable (data not shown), confirming that the loss of histochemical titre of hybrid B (Figure 2 ) was largely due to reduced transduction efficiency.
The level of expression per copy number driven by the hybrid F and wild-type LTRs was calculated from the ␤-galactosidase enzyme activity produced from a known number of infected cells, and their proviral copy number determined above. The ␤-galactosidase expression level driven by the hybrid LTR in PAE cells was approximately 10-fold higher than TE671 cells, and represented 15% of that driven by the wild-type LTR (Table 2) .
Endothelial cell-specific expression from the hybrid F LTR High titre virus harvests of ELH-F20 and the control virus MFGnlslacz were used to infect a number of endothelial and non-endothelial cell lines. Since it was not possible to determine the pg per copy number by Southern analysis of poorly infectable cell types such as HUVEC, HMEC-1 and ECV304, for each cell type the ␤-galactosidase activity produced by a number of cells Gene Therapy Table 1 . Provirus copy numbers were determined by Southern blot analysis (see Figure 3 and Table 1 ). ␤-Galactosidase enzyme activities were determined and normalised to the copy number to yield the level of activity per transduced cell due to either the wild-type or the hybrid F LTR. ␤-Galactosidase activity of cells infected with ELH-F20 was calculated as the percentage of cells infected with the MFGnlslacz control, normalised for differences in titre between the two viruses (see text). Data shown are mean ± standard error of at least six determinations from infection experiments using two virus harvests. For the poorly infectable HUVEC and HMEC-1, the harvest with the highest titre was used for determinations.
infected with ELH-F20 was calculated as the percentage of that expressed by an equivalent number of cells infected with the control virus MFGnlslacz at the same dilution, normalized for differences in titre between ELH-F20 and MFGnlslacz (Table 3) . With reference to parallel histochemical staining, for each cell type the lowest dilution was chosen for which infection by the the control virus was not saturating. The difference in viral titre between ELH-F20 and the MFGnlslacz was determined from parallel histochemical assay on PAE cells. From the calculated pg per transduced cell for ELH-F20, the hybrid F LTR showed over 10-fold specificity of expression in PAE, HUVEC and HMEC-1 compared with the nonendothelial HT1080, TE671 and ECV304 (Figure 4) . Expression level was also low in EAhy926.
Assessment of in vivo specificity in a subcutaneous tumour model
The in vivo activity of ELH-F20 virus was assessed in subcutaneous xenografts grown in nude mice. In order to achieve optimal levels of transduction, irradiated virus producer cells were co-injected with tumour cells as described in Materials and methods. In this subcutaneous tumour model, transduction takes place during tumour growth. We have shown that irradiated producer cells efficiently release virus in culture for at least 2 weeks
Figure 4 Endothelial cell specificity of the hybrid LTR. A panel of endothelial and non-endothelial cell lines were infected with ELH-F20 and the control virus MFGnlslacz for determination of ␤-galactosidase expression. Hybrid LTR activity was calculated from the percentage wild-type activity and the absolute value pg/transduced cell for the wild-type LTR (Table 3).
(unpublished data). In order to estimate how long virus producer cells persisted in vivo, we histochemically stained tumours resulting from the co-injection of KS-Y-1 cells and irradiated TE671 cells that stably expressed ␤-galactosidase. Only a very small number of blue cells (representing less than 0.5% of the total number of tumour cells on a section) was detectable in small tumours (3 mm in diameter) 12 days following co-injection, whereas no blue TE671 cells could be detected in tumours 3 weeks following subcutaneous injection. KS Y-1 tumours grown subcutaneously were chosen as a model, as they were well vascularized with readily identifiable blood vessels (Figure 5a ). These were embedded in host stroma surrounding nests of KS Y-1 tumour cells, and showed high immunoreactivity with an antibody against mouse CD31 (data not shown). Furthermore, the hybrid F LTR had undetectable activity in KS Y-1 cells in vitro (data not shown). Irradiated virus producer cells (producing control MFGnlslacz or ELH-F20 virus) were co-injected with KS Y-1 cells. Tumours were grown for at least 14 days before they were excised and stained for ␤-galactosidase expression. A large number of histochemically positive cells, including KS Y-1 tumour cells and endothelial cells, could be detected throughout tumours arising from the co-injection of KS Y-1 cells and MFGnlslacz producers (Figure 5b) . In agreement with the in vitro specificity of the hybrid F LTR, in tumours arising from the co-injection of KS Y-1 and ELH-F20 producers, ␤-galactosidase expression was localized in endothelial cells in the host vasculature, but not in nests of KS Y-1 tumour cells (Figure 5c ).
The activity of ELH-F20 virus was further tested in human colorectal tumours grown as xenografts in nude mice. The KM-12, mawi and HCT-116 lines tested also a b c
Figure 5 Specificity of ELH-F20 in subcutaneous KS Y-1 xenografts. (a) Haematoxylin-eosin stain of subcutaneous KS Y-1 tumours grown in nude mice (× 20). Endothelial cells (arrows) are embedded in host stroma (S) surrounding tumour nests (T). (b and c) X-gal staining of KS Y-1 tumours transduced with the control virus MFGnlslacz (b) or the modified virus ELH-F20 (c) (see text). Sections were counterstained with haematoxylin and eosin. The results are representative of tumours transduced with the control or the modified virus, from at least four animals.
gave rise to well vascularised subcutaneous tumours with easily identifiable blood vessels. In a similar pattern to that observed in KS Y-1 tumours, a large number of positive cells, including tumour cells and endothelial cells, could be detected throughout tumours arising from the co-injection of tumour cells (eg mawi) and MFGnlslacz producers (data not shown). In contrast, expression driven by the hybrid F LTR was restricted to the tumour vasculature, in tumours arising from the co-injection of tumour epithelial cells and ELH-F20 producers ( Figure 6 ).
Discussion
We have introduced sequences controlling endothelial cell-specific expression into recombinant retroviral vectors, as a means of targeting gene expresssion to endothelial cells in the tumour vasculature. We have explored different strategies for incorporating heterologous regulatory sequences of the prepro-endothelin-1 (ppET1) promoter in the 3Ј LTR of retroviral vectors, aiming to achieve good titres and optimal specificity. We have assessed specificity both in vitro, using a panel of endothelial and non-endothelial cells, and in vivo, in subcutaneous tumours arising from the co-injection of tumour cells and irradiated virus producer cells.
We chose not to incorporate selectable markers in our recombinant retroviruses, as the strong promoters used to drive their expression may interfere with heterologous regulatory sequences, compromising specificity. We also anticipated that without the potential for selection to bias expression, the performance of such modified retroviral vectors in vitro would reflect more accurately their behaviour in vivo. The absence of a selectable marker inevitably complicates analysis, mainly at the level of determination of transduction efficiencies. This is because the histochemical titre of the modified viruses can be affected by both their viral titre and the expression level driven by the modified LTR. Another difficulty in analysing these vectors is the requirement to achieve high transduction efficiencies from high titre viruses for the determination of expression levels from bulk populations of infected cells.
A number of strategies were compared for incorporating ppET1 promoter regulatory sequences in the 3Ј LTR. Replacement of both the viral enhancer and viral promoter region with ppET1 promoter sequences conferred transcriptional specificity in PAE compared with TE671 cells, although the modification also resulted in reduced histochemical titres of both retroviral vectors generated using this strategy (hybrids A and B). Diaz and colleagues 16 have previously replaced the promoter and enhancer elements of the viral LTR with the tyrosinase promoter and enhancer sequences in pBabePuro without loss of titre. In our study, it was necessary to maintain the proximal promoter sequences (hybrids E and F), in order to obtain titres comparable to those of the control vector with an unmodified LTR. We are currently investigating the basis of this observation. The small reduction in titre of hybrid E (incorporating both the ppET1 and viral TATA boxes), may be associated with premature termination of transcription, due to the distance of the ppET1 TATA box from the viral polyadenylation sequences in the R region of the 5Ј LTR. Termination in the 5Ј LTR is usually silent due to the proximity Gene Therapy a b c
Figure 6 Endothelial cell-specific expression of ELH-F20 in subcutaneous colorectal xenografts. X-gal staining of colorectal tumours transduced with modified virus ELH-F20 (see text). Sections were counterstained with haematoxylin and eosin. Endothelial cells (arrows) expressing the ␤-galactosidase reporter gene were detected in the vasculature of KM-12 (a), mawi (b), and HCT-116 (c) subcutaneous tumours grown in nude mice. (T) tumour cells, (S) host stroma.
of the viral start site and 5Ј polyadenylation site, and/or lack of upstream RNA sequences at the 5Ј end of the viral transcript. In the optimal strategy (hybrid F), replacement of the viral enhancer with promoter sequences preceding the ppET1 TATA box, incorporating the GATA and AP1-like elements, resulted both in optimal titres and endothelial specificity. Although these proximal promoter elements have not been previously analysed in the context of heterologous promoters, they are known to be essential for the endothelial-specific activity of the ppET1 promoter via binding of GATA-2 and fos/jun transcription factors, respectively. 22, 23 Specificity was assessed in vitro using a panel of endothelial and non-endothelial cell lines and was found to match the activity of the endogenous ppET1 promoter assayed by RT-PCR (data not shown). There was approximately 10-fold preferential expression driven by the targeted LTR in PAE, HUVEC and HMEC-1 compared with the non-endothelial TE671, HT1080 and ECV 304, consistent with the activity of the endogenous promoter in these cells. The level of expression, approximately 15% of that driven by the unmodified LTR, is likely to be related to the intrinsic activity of the ppET1 promoter.
Since models for efficient systemic delivery of retroviral vectors are not yet fully developed, we have used a co-injection xenograft model to achieve transduction in vivo. In summary, we have optimised a strategy for generating high titre retroviral vectors for endothelial-specific transcriptional targeting from a prepro-endothelin-1 promoter hybrid LTR. We have obtained good specificity, both in vitro and in an in vivo model of subcutaneous coinjection of tumour cells and virus producer cells, that can be routinely used to screen the performance of targeted retroviruses. Our approach is likely to be valuable for the development of cancer gene therapy strategies aimed to disrupt the tumour vasculature by targeting its endothelial lining.
Materials and methods
Cell lines PAE (porcine aorta endothelial cell), human cell lines TE671 (rhabdomyosarcoma), HT1080 (fibrosarcoma), ECV304 (now known to be equivalent to T24 bladder carcinoma), EAhy926 (HUVEC-derived, by fusion with A549 lung carcinoma cells), Kaposi's sarcoma derived KS Y-1, 26 and human colorectal lines KM-12, mawi, HCT-116 were maintained in DMEM supplemented with 10% FCS. TE-FLY-A8 (F-L Cosset, unpublished) amphotropic retroviral packaging cell line was similarly maintained.
HMEC-1 (SV40 T-antigen transformed human dermal microvascular endothelial cell) 27 and HUVEC (ATCC CRL-1730) were maintained in microvascular endothelial cell growth medium (Clonetics Corporation, obtained from TCS Biologicals, Buckingham, UK).
Cloning of the human ppET1 promoter region ppET1 promoter sequences between positions −177 to +33 relative to the transcription start site were amplified by PCR from human genomic DNA. Numbering is based on EMBL database entry HSETN1. 20 The primers used (refer to Figure 1 ) were 5Ј-GCGAGATCTGCCTCTGAA GTTAGCAGTG, incorporating a BglII restriction site, and 5Ј-GCAGGATCCGTTCGCCTGGCGCAGATG (ETP3A), incorporating a BamHI restriction site. PCR conditions were 30 cycles of 30 s at 94°C, 1 min at 60°C, 30 s at 72°C. Amplified products were digested with BglII and BamHI cloned into these sites in pSP72 (Promega, Southampton, UK) and verified by DNA sequencing. 28 Construction of retroviral vectors with hybrid ppET1/LTR promoter Plasmid p⌬BN, containing a neomycin resistance (neo R ) cassette and a single MLV LTR with a 3Ј flanking NotI restriction site, was derived by partial deletion of sequences between the PstI sites in pBabeneo. 29 The multiple cloning site was subsequently destroyed by digestion with BamHI and SalI, followed by end-repair with Klenow polymerase and religation. The 5.5 kb NheI fragment from pMFGnlslacz 30 was inserted into the unique NheI site to create pNeoMFGnlslacz, equivalent to pMFGnlslacz but also incorporating an SV40.neo R cassette outside the retroviral transcription unit and the 3Ј flanking NotI site to facilitate exchange of 3Ј LTR sequences.
Hybrid vectors were constructed by cloning ppET1 promoter sequences into p⌬BN and verified by DNA sequencing. NheI/NotI fragments from the hybrids were used to replace the 3Ј LTR in pNeoMFGnlslacz, following NotI and partial NheI digestion. To generate hybrids A and E, the −177 to +33 region was amplified from the cloned ppET1 promoter and used to replace the NheI/SstI (hybrid A) and NheI/XbaI (hybrid E) fragments of the MLV LTR in p⌬BN. The forward primer was 5Ј-ATA GCTAGCTCTGCCTCTGAAGTTAGCAGTG (ETP5Nhe), and reverse primers were 5Ј-ATAGAGCTCCGTTCGC CTGGCGCAGATG (ETP3ASst) or 5Ј-ATATCTAGACCG TTCGCCTGGCGCAGATG (ETP3AXba), incorporating NheI, SstI and XbaI restriction sites (Figure 1 ). To generate hybrids B and F, the −177 to −37 region of the ppET1 promoter was amplified using the ETP5Nhe forward primer, and reverse primers 5Ј-ATAGAGCTCCCCTAT TAGAGTGGGGGTAAAC (ETP3TATASst) or 5Ј-ATATCTA GACCCTATTAGAGTGGGGGTAAAC (ET3TATAXba), and used to replace the NheI/SstI (hybrid B) and NheI/XbaI (hybrid F) fragments of the MLV LTR in p⌬BN. PCR conditions were 25 cycles of 30 s at 94°C, 1 min at 60°C, 1 min at 72°C. Hybrid C was generated following partial NheI digestion of hybrid B, by insertion of the NheI/XbaI LTR fragment containing the MLV enhancer into the 3Ј LTR, in an orientation identical to that in the unmodified LTR. For the generation of hybrid D, the human cytomegalovirus (CMV) enhancer was subcloned into the vector pUC1813, 31 and then inserted as a XbaI fragment, in the forward orientation in the 3Ј LTR, following partial NheI digestion of hybrid B.
Recombinant retroviral vectors
The packaging cell line TE-FLY-A8 (Cosset, unpublished), a TE671-based equivalent of FLY-A13, 25 was used to generate all recombinant retroviral viruses following CaPO 4 -mediated transfection of plasmid DNA. Stable transfectants were selected in 1 mg/ml G418. Virus was harvested following overnight incubation of confluent monolayers in fresh medium and filtered (0.45 m). Target cells were infected with serial dilutions of virus in the presence of 8 g/ml polybrene for 4-6 h. Culture medium was changed and cells were histochemically stained 2-3 days later using 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal). ELH-F20, a high titre ppET1/LTR hybrid F virus was obtained from the producer clone with the highest titre on PAE cells. High titre virus MFGnlslacz from the producer clone TELCeB6AF 25 was used as a control. Since virus prepared in this way can contain factors that are inhibitory for transduction, 32 care was taken to ensure that titres and ␤-galactosidase enzyme activities were determined from virus concentrations at which the infection efficiency diluted linearly.
Southern blot analysis of proviruses in transduced cells
Genomic DNA (10 g) from infected cells was digested with NheI, separated by electrophoresis, and transferred to Hybond-N + membrane (Amersham International, Buckinghamshire, UK). For hybridization a 32 P-dCTPlabelled 3.5 kb DNA fragment encoding the nlslacz gene was used. Quantification was performed on a STORM 860 phospho-imager (Molecular Dynamics, Kemsing, UK). For quantitation of proviral copy number, DNA from uninfected cells was mixed with copy number equivalents of plasmid DNA containing the nlslacz gene, and treated as above.
Determination of ␤-galactosidase enzyme activity A quantitative photometric assay was used to determine ␤-galactosidase activity in cell lysates. 33 Cells in 24-well plates were infected with 500 l virus supernatant at the appropriate dilution, as described above. After 2 days in culture, cells were washed in PBS, lysed in 350 l 250 mm Tris HCl, pH 8.0, 0.1% Triton X-100, and lysates were stored at −80°C. For the ␤-galactosidase assays, 50 l lysate or dilutions were incubated with 50 l PBS, 0.5% bovine serum albumin and 150 l 60 mm Na 2 HPO 4 , pH 8.0, 1 mm MgSO 4 , 10 mm KCl, 50 mm ␤-mercaptoethanol, 0.1% CPRG (chlorophenol red galactopyranoside; Boehringer Mannheim, Lewes, UK). Following incubation at 37°C in the dark, absorption was measured at 570 nm and converted to picograms of expressed ␤-galactosidase from a standard curve obtained using purified enzyme (Sigma, Poole, UK).
Subcutaneous co-injection of cells and X-gal histochemistry Kaposi's sarcoma derived KS Y-1 cells (1 × 10   6 ), or the colorectal lines KM-12, mawi, HCT-116 (1.5 × 10 6 ) were co-injected subcutaneously with virus producer cells at a 1:5 ratio (tumour:producer) into 4-6-week-old nu/nu mice (Harlan, Oxford, UK). Before mixing, the virus producer cells were X-irradiated (20 Gy). Animals were killed 15-25 days after injection. For histochemical analyGene Therapy sis the excised tumours were fixed in 4% paraformaldehyde for 30 min, stained overnight with X-gal, and embedded in paraffin blocks. Sections (10 m) were deparaffinized and counterstained with haematoxylin and eosin.
